Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis.
메타분석
1/5 보강
[BACKGROUND] Hepatocellular carcinoma (HCC) prognosis remains poor in advanced stages.
- 95% CI 1.40–1.72
- HR 0.54
- RR 1.55
- 연구 설계 meta-analysis
APA
Hou S, Hu S, et al. (2025). Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis.. BMC cancer, 25(1), 1602. https://doi.org/10.1186/s12885-025-15061-4
MLA
Hou S, et al.. "Efficacy and safety of stereotactic body radiation therapy combined with targeted agents and immunotherapies in hepatocellular carcinoma: a systematic review and meta-analysis.." BMC cancer, vol. 25, no. 1, 2025, pp. 1602.
PMID
41107761 ↗
Abstract 한글 요약
[BACKGROUND] Hepatocellular carcinoma (HCC) prognosis remains poor in advanced stages. Stereotactic body radiation therapy (SBRT) combined with pharmacological agents (targeted therapies/immunotherapies) represents a promising multimodal strategy, but its efficacy and safety require comprehensive evaluation.
[METHODS] This meta-analysis included 9 studies ( = 20,812). The adverse event analysis covered the overall adverse event data from 7 studies ( = 583) and grade ≥ 3 adverse events from 4 studies ( = 303). The survival outcome analysis included 9 studies ( = 20,781) and the progression-free survival analysis included 4 studies ( = 424). Hazard ratios (HRs) and risk ratios (RRs) with 95% CIs were calculated via fixed/random effects models.
[RESULTS] Compared with pharmacological agents, SBRT combined with pharmacological agents significantly improved 1-year OS (RR = 1.55, 95% CI:1.40–1.72), 2-year OS (RR = 1.63, 95% CI:1.33–1.99), objective response rate (RR = 1.87, 95% CI:1.52–2.39) and reduced mortality risk (HR = 0.54, 95% CI:0.40–0.72), progression risk (HR = 0.49, 95% CI:0.38–0.63) without increasing overall adverse events (RR = 1.03, 95% CI:0.98–1.09) or grade ≥ 3 toxicities (RR = 1.12, 95% CI:0.92–1.36).
[CONCLUSION] SBRT combined with pharmacological agents significantly improves survival and tumor response in advanced HCC without increasing overall toxicity. This synergy supports the integration of SBRT into systemic therapy paradigms for HCC.
[TRIAL REGISTRATION] PROSPERO CRD420251040157.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15061-4.
[METHODS] This meta-analysis included 9 studies ( = 20,812). The adverse event analysis covered the overall adverse event data from 7 studies ( = 583) and grade ≥ 3 adverse events from 4 studies ( = 303). The survival outcome analysis included 9 studies ( = 20,781) and the progression-free survival analysis included 4 studies ( = 424). Hazard ratios (HRs) and risk ratios (RRs) with 95% CIs were calculated via fixed/random effects models.
[RESULTS] Compared with pharmacological agents, SBRT combined with pharmacological agents significantly improved 1-year OS (RR = 1.55, 95% CI:1.40–1.72), 2-year OS (RR = 1.63, 95% CI:1.33–1.99), objective response rate (RR = 1.87, 95% CI:1.52–2.39) and reduced mortality risk (HR = 0.54, 95% CI:0.40–0.72), progression risk (HR = 0.49, 95% CI:0.38–0.63) without increasing overall adverse events (RR = 1.03, 95% CI:0.98–1.09) or grade ≥ 3 toxicities (RR = 1.12, 95% CI:0.92–1.36).
[CONCLUSION] SBRT combined with pharmacological agents significantly improves survival and tumor response in advanced HCC without increasing overall toxicity. This synergy supports the integration of SBRT into systemic therapy paradigms for HCC.
[TRIAL REGISTRATION] PROSPERO CRD420251040157.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-15061-4.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- The miR-181d-5p/SPP1 axis inhibits the migration and invasion of colorectal cancer via the RhoA patyway.
- The prognostic value of immunoscore in colorectal cancer liver metastases: a meta-analysis reveals the superiority of metastatic over primary tumor profiling.
- Modulation of NF-κB and oxidative stress pathways in ethanol-induced gastric injury by a multi-component herbal formula: An in vivo study.
- Intelligent Diagnosis of Follicular Carcinoma Thyroid Cancer with a Novel Deep Learning Model.
- Impact of aging on colon cancer burden: A cross-sectional analysis of nationally representative data.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- SLC2A1 tumour-associated macrophages spatially control CD8 T cell function and drive resistance to immunotherapy in non-small-cell lung cancer.
- Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.
- Heat Shock Protein 47 as a Novel Predictive and Diagnostic Biomarker for Thrombosis in Hepatocellular Carcinoma.
- Immune Checkpoint Inhibitors for Recurrent Hepatocellular Carcinoma After Liver Transplantation: Safety Under an Immunosuppression-Preserving Strategy.
- Crosstalk Between -Regulatory Elements and Metabolism Reprogramming in Hepatocellular Carcinoma.